Zusammenfassung
Ein wesentlicher Pfeiler der Therapie des fortgeschrittenen Nierenzellkarzinoms ist heute die Behandlung mit Tyrosinkinaseinhibitoren. Das Hand-Fuß-Syndrom ist eine häufige Nebenwirkung dieser Therapie und schränkt je nach Schweregrad die Lebensqualität der Patienten oft erheblich ein. Eine effektive Behandlung ist daher entscheidend und eine Standardisierung der Behandlungsempfehlungen wünschenswert. Das vorliegende Manuskript stellt praxisnahe und standardisierte Behandlungsempfehlungen insbesondere für die ambulante Versorgung in der urologisch-onkologischen Praxis vor und diskutiert verschiedene Strategien für Prophylaxe und Therapie des Hand-Fuß-Syndroms.
Abstract
A significant component of advanced renal cell carcinoma therapy is treatment with tyrosine kinase inhibitors. Hand-foot syndrome is a frequent adverse reaction and the quality of life of patients can be considerably affected depending on the severity. Effective treatment options are, therefore, essential and standardization of treatment recommendations is desirable. In this article practical and standardized recommendations for the treatment of outpatients with hand-foot syndrome are introduced and several strategies for prophylaxis and therapy are discussed.
This is a preview of subscription content, log in via an institution to check access.
Literatur
Chu D, Lacouture ME, Fillos T, Wu S (2008) Risk of hand-foot skin reaction with sorafenib: a systematic review and meta-analysis. Acta Oncol 47:176–186
Chu D, Lacouture ME, Weiner E, Wu S (2009) Risk of hand-foot skin reaction with the multitargeted kinase inhibitor sunitinib in patients with renal cell and non-renal cell carcinoma: a meta-analysis. Clin Genitourin Cancer 7:11–19
Fischer A, Wu S, Ho AL, Lacouture ME (2013) The risk of hand-foot skin reaction to axitinib, a novel VEGF inhibitor: a systematic review of literature and meta-analysis. Invest New Drugs 30(4):1773–1781
Balagula Y, Wu S, Su X et al (2012) The risk of hand-foot skin reaction to pazopanib, a novel multikinase inhibitor: a systematic review of literature and meta-analysis. Invest New Drugs 30:1773–1781
Wood LS, Lemont H, Jatoi A et al (2010) Practical considerations in the management of hand-foot skin reaction caused by multikinase inhibitors. Community Oncol 7:23–29
Zuehlke RL (1974) Erythematous eruption of the pamls and soles associated with mitotane therapy. Dermatologica 148:90–92
Baack BR, Burgdorf WH (1991) Chemotherapy-induced acral erythema. J Am Acad Dermatol 24:457–461
Degen A, Alter M, Schenck F et al (2010) The hand-foot-syndrome associated with medical tumor therapy – classification and management. J Dtsch Dermatol Ges 8:652–661
Lacouture ME, Wu S, Robert C et al (2008) Evolving strategies for the management of hand-foot skin reaction associated with the multitargeted kinase inhibitors sorafenib and sunitinib. Oncologist 13:1001–1011
Martschick A, Sehouli J, Patzelt A et al (2009) The pathogenetic mechanism of anthracycline-induced palmar-plantar erythrodysesthesia. Anticancer Res 29:2307–2314
Kollmannsberger C, Bjarnason G, Burnett P et al (2011) Sunitinib in metastatic renal cell carcinoma: recommendations for management of noncardiovascular toxicities. Oncologist 16:543–553
Wollenberg A, Staehler M, Eames T (2010) Kutane Nebenwirkungen der Multikinaseinhibitoren Sorafenib und Sunitinib. Hautarzt 61:662–667
Lopez AM, Wallace L, Dorr RT et al (1999) Topical DMSO treatment for pegylated liposomal doxorubicin-induced palmar-plantar erythrodystesthesia. Cancer Chemother Pharmacol 44:303–306
Robert C, Mateus C, Spatz A et al (2009) Dermatologic symptoms associated with the multikinase inhibitor sorafenib. J Am Acad Dermatol 60:299–305
Strumberg D, Awada A, Hirte H et al (2006) Pooled safety analysis of BAY 43–9006 (sorafenib) monotherapy in patients with advanced solid tumours: is rash associated with treatment outcome? Eur J Cancer 42:548–556
Donskov F, Michaelson MD, Puzanov I et al (2012) Comparative assessment of Sunitinib-associated adverse events as potential biomarkers of efficacy in metastatic renal cell carcinoma (mRCC). European Society for Medical Oncology, Vienna
Huptas L, Rompoti N, Herbig S et al (2011) Schmerzreduktion bei Patienten mit chronischem Ulcus cruris durch ein neu entwickeltes Morphingel. Hautarzt 62:280–286
Kara IO, Sahin B, Erkisi M (2006) Palmar-plantar erythrodysesthesia due to docetaxel-capecitabine therapy is treated with vitamin E without dose reduction. Breast 15:414–424
Podlekareva Farr K, Safwat A (2011) Palmar-plantar erythrodysesthesia associated with chemotherapy and its treatment. Case Rep Oncol 4:229–235
Mangili G, Petrone M, Gentile C et al (2008) Prevention strategies in palmar-plantar erythrodysesthesia onset: the role of regional cooling. Gynecol Oncol 108:332–335
Kingsley EC (1994) 5-fluorouracil dermatitis prophylaxis with a nicotine patch. Ann Intern Med 120:813
Interessenkonflikt
Der korrespondierende Autor weist für sich und seinen Koautor auf folgende Beziehung hin: Diese Publikation wurde von der Firma Pfizer finanziell unterstützt.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Burbach, G., Zuberbier, T. Hand-Fuß-Syndrom bei Tyrosinkinaseinhibitortherapie. Urologe 52, 1574–1578 (2013). https://doi.org/10.1007/s00120-013-3204-7
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00120-013-3204-7